Review
Radiology, Nuclear Medicine & Medical Imaging
Hyunmin Kim, Da In Lee, Sung Kyoung Moon, Seong Jin Park, Myung-Won You
Summary: Perianal fistulas in Crohn's disease require both medical and surgical treatment. MRI evaluation is important for detailed information on the type and activity of the fistula, as well as associated complications. The use of a structured MR report is recommended for initial diagnosis and disease monitoring.
EUROPEAN JOURNAL OF RADIOLOGY
(2023)
Article
Gastroenterology & Hepatology
Laura Maas, Ruiyi Gao, Vivy Cusumano, Ellen Spartz, Reezwana Chowdhury, Mahesh Krishna, Mark Lazarev, Joanna Melia, Florin Selaru, Sowmya Sharma, Berkeley Limketkai, Alyssa Parian
Summary: This study compared the efficacy of infliximab (IFX) and adalimumab (ADA) in healing CD-PAF. The results showed that the IFX group had better clinical response at 6 months and higher biologic persistence. In addition, the study supported the use of concomitant immunomodulator therapy for CD-PAF healing and remission.
DIGESTIVE DISEASES AND SCIENCES
(2023)
Article
Gastroenterology & Hepatology
Bonita Gu, Kavya Venkatesh, Astrid-Jane Williams, Watson Ng, Crispin Corte, Ali Gholamrezaei, Simon Ghaly, Wei Xuan, Sudarshan Paramsothy, Susan Connor
Summary: Maintenance infliximab and adalimumab trough levels are associated with perianal fistula healing in CD. Patients who achieved fistula healing had significantly higher drug trough levels compared to those who did not.
WORLD JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Gastroenterology & Hepatology
Mingming Zhu, Xitao Xu, Qi Feng, Zhe Cui, Tianrong Wang, Yunqi Yan, Zhihua Ran
Summary: The study demonstrated that infliximab induced deep radiological remission of perianal fistulas in Chinese patients with CD. Combined therapy using infliximab with azathioprine increased the fistula healing rate, while younger age at CD diagnosis, proctitis, and requiring perianal surgery were identified as predictors of poor deep radiological remission of fistulas.
DIGESTIVE DISEASES AND SCIENCES
(2021)
Article
Medicine, General & Internal
Bonita Gu, Michael De Gregorio, Joseph Louis Pipicella, Niels Vande Casteele, Jane M. Andrews, Jakob Begun, William Connell, Basil D'Souza, Ali Gholamrezaei, Ailsa Hart, Danny Liew, Graham Radford-Smith, Jordi Rimola, Tom Sutherland, Catherine Toong, Rodney Woods, Yang Wu, Wei Xuan, Astrid-Jane Williams, Watson Ng, Nik Sheng Ding, Susan Connor
Summary: This study aims to assess whether infliximab therapy targeting higher trough levels guided by proactive therapeutic drug monitoring improves outcomes compared with standard therapy for patients with perianal fistulising Crohn's disease (pfCD). The study will include a 54-week follow-up period, with the primary objective of observing fistula healing at week 32.
Article
Surgery
Jacopo Crippa, Antonino Spinelli
Summary: This review provides insights into the diagnostic, medical, and surgical pathways for perianal Crohn's disease.
BRITISH JOURNAL OF SURGERY
(2022)
Article
Gastroenterology & Hepatology
Jessica Breton, Ceylan Tanes, Vincent Tu, Lindsey Albenberg, Sarah Rowley, Nina Devas, Rosa Hwang, Kelly Kachelries, Gary D. Wu, Robert N. Baldassano, Kyle Bittinger, Peter Mattei
Summary: The microbial community in children with perianal fistulising CD is different in composition and function compared to other CD patients and healthy children, highlighting the importance of understanding the microbiome in the perianal milieu for developing treatment strategies.
JOURNAL OF CROHNS & COLITIS
(2022)
Review
Gastroenterology & Hepatology
Benedicte Caron, Ferdinando D'Amico, Silvio Danese, Laurent Peyrin-Biroulet
Summary: This systematic review described the evolution of endpoints in randomized controlled trials of perianal Crohn's disease patients and observed significant changes in outcomes used in these trials, indicating the increasing use of radiological endpoints in studies of perianal fistulizing Crohn's disease.
JOURNAL OF CROHNS & COLITIS
(2021)
Review
Gastroenterology & Hepatology
Alyssa M. Parian, Megan Obi, Phillip Fleshner, David A. Schwartz
Summary: Perianal Crohn's disease is a difficult complication of Crohn's disease to treat, affecting 25%-35% of patients. It leads to lower health-related quality of life scores, higher hospitalization rates, surgeries, and healthcare costs. A multidisciplinary approach involving medical and surgical management, including the use of stem cell therapy, is necessary for successful treatment.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Medicine, General & Internal
Mir Zulqarnain, Parakkal Deepak, Andres J. Yarur
Summary: Perianal fistulas are a common complication of Crohn's disease and can be challenging to manage. Although anti-TNF agents are effective in treating perianal fistulizing Crohn's disease, some patients do not respond to therapy. Therapeutic drug monitoring is considered an important tool to optimize and guide biologic treatment and could improve outcomes for patients with perianal fistulas.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Medicine, General & Internal
Ali Alyami, Caroline L. Hoad, Christopher Tench, Uday Bannur, Christopher Clarke, Khalid Latief, Konstantinos Argyriou, Alan Lobo, Philip Lung, Rachel Baldwin-Cleland, Kapil Sahnan, Ailsa Hart, Jimmy K. Limdi, John Mclaughlin, David Atkinson, Geoffrey J. M. Parker, James P. B. O'Connor, Ross A. Little, Penny A. Gowland, Gordon W. Moran
Summary: Quantitative MRI sequences can be used to monitor and diagnose perianal Crohn's Disease, with baseline PDAI, CRP, T2 relaxometry, and surgical history showing moderate ability to predict response after 12 weeks of biological treatment. Further validation in larger cohorts with MRI and clinical measures is needed for model development.
Article
Gastroenterology & Hepatology
Ping Zhu, Jin-fang Sun, Yun-fei Gu, Hong-jin Chen, Min-min Xu, You-ran Li, Bo-lin Yang
Summary: This retrospective cohort study aimed to determine the long-term efficacy of early initiation of infliximab following surgery among PFCD patients. The results showed no clear benefit between early and delayed infliximab induction groups in terms of surgical re-intervention and fistula healing.
BMC GASTROENTEROLOGY
(2022)
Review
Gastroenterology & Hepatology
Abhinav Vasudevan, David H. Bruining, Edward V. Loftus, William Faubion, Eric C. Ehman, Laura Raffals
Summary: Perianal Crohn's disease is challenging to treat and often requires a combination of surgical and medical interventions. Anti-TNF therapy, such as infliximab and adalimumab, is preferred and has been shown to be efficacious in improving fistula closure rates. Clinicians face various questions regarding the optimal use of anti-TNF therapy for perianal Crohn's disease, including evaluation for sepsis, treatment target, ideal timing, and duration of treatment.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Gastroenterology & Hepatology
Shuang-Shuang Lu, Wen-Jia Liu, Qiu-Ya Niu, Chun-Yan Huo, Yu-Qing Cheng, En-Jing Wang, Rong-Nan Li, Fang-Fang Feng, Yi-Ming Cheng, Rong Liu, Jin Huang
Summary: In this study, an improved method of inducing colitis in rabbits successfully established a reliable and reproducible animal model of perianal fistulizing Crohn's disease, which was confirmed by endoscopy and histology.
WORLD JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Medicine, General & Internal
Feihong Deng, Pianpian Xia, Zengrong Wu, Hejun Zhou, Xuehong Wang
Summary: This study showed that the rate of perianal relapse in patients with perianal Crohn's disease after surgical remission was significantly reduced with Infliximab therapy compared to nonbiological treatment. However, around 40% of patients using Infliximab still experienced perianal relapse at 5 years, with factors such as discontinuation of IFX therapy, a penetrating phenotype, or a complex perianal fistula associated with increased relapse rate.
INTERNATIONAL JOURNAL OF GENERAL MEDICINE
(2021)
Article
Oncology
Simon Zaibet, Vincent Hautefeuille, Edouard Auclin, Astrid Lievre, David Tougeron, Mathieu Sarabi, Marine Gilabert, Julie Wasselin, Julien Edeline, Pascal Artru, Dominique Bechade, Clemence Morin, Agnes Ducoulombier, Julien Taieb, Simon Pernot
Summary: This study evaluates the efficacy and safety of adding Nab-paclitaxel to Gem for metastatic pancreatic adenocarcinoma (mPA) after FOLFIRINOX failure. The results show that Gem-Nab is associated with better disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) compared with Gem alone, but with higher toxicity.
BRITISH JOURNAL OF CANCER
(2022)
Correction
Oncology
Sonia Zaibet, Vincent Hautefeuille, Edouard Auclin, Astrid Lievre, David Tougeron, Mathieu Sarabi, Marine Gilabert, Julie Wasselin, Julien Edeline, Pascal Artru, Dominique Bechade, Clemence Morin, Agnes Ducoulombier, Julien Taieb, Simon Pernot
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Mathias Brugel, Lea Letrillart, Camille Evrard, Aurore Thierry, David Tougeron, Mehdi El Amrani, Guillaume Piessen, Stephanie Truant, Anthony Turpin, Christelle D'Engremont, Gael Roth, Vincent Hautefeuille, Jean M. Regimbeau, Nicolas Williet, Lilian Schwarz, Frederic Di Fiore, Christophe Borg, Alexandre Doussot, Aurelien Lambert, Valerie Moulin, Helene Trelohan, Marion Bolliet, Amalia Topolscki, Ahmet Ayav, Anthony Lopez, Damien Botsen, Tulio Piardi, Claire Carlier, Olivier Bouche
Summary: The COVID-19 pandemic has had a significant impact on the diagnosis and treatment of pancreatic adenocarcinoma. During the lockdown, there was a decrease in new cases and an increase in borderline tumors, while the rate of metastatic diseases decreased. There was no difference in time-to-diagnosis and time-to-treatment. Neoadjuvant chemotherapy was favored over upfront surgery, and the use of a specific preoperative chemotherapy regimen decreased. After the lockdown, there was a decrease in borderline tumors and an increase in advanced diseases.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Quang Loc Bui, Leo Mas, Antoine Hollebecque, David Tougeron, Christelle de la Fouchardiere, Thomas Pudlarz, Emily Alouani, Rosine Guimbaud, Julien Taieb, Thierry Andre, Raphael Colle, Romain Cohen
Summary: This study retrospectively collected clinical data from 31 patients with dMMR/MSI mCRC. The results showed that there was no improved outcome with CT after ICI failure, but prolonged disease control was observed in some cases.
Article
Biochemistry & Molecular Biology
Camille Evrard, Stephane Messina, David Sefrioui, Eric Frouin, Marie-Luce Auriault, Romain Chautard, Aziz Zaanan, Marion Jaffrelot, Christelle De la Fouchardiere, Thomas Aparicio, Romain Coriat, Julie Godet, Christine Silvain, Violaine Randrian, Jean-Christophe Sabourin, Rosine Guimbaud, Elodie Miquelestorena-Standley, Thierry Lecomte, Valerie Moulin, Lucie Karayan-Tapon, Gaelle Tachon, David Tougeron
Summary: This study demonstrates a high concordance rate of dMMR/MSI status between primary colorectal cancers and their metastases, suggesting that analyzing the consistent dMMR and MSI status from either the primary tumor or metastasis sample is sufficient prior to treatment with immune checkpoint inhibitors.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Medicine, General & Internal
Nicolas Chapelle, Malgorzata Osmola, Jerome Martin, Justine Blin, Maxime Leroy, Iva Jirka, Driffa Moussata, Dominique Lamarque, Raphael Olivier, David Tougeron, Anne Hay-Lombardie, Edith Bigot-Corbel, Damien Masson, Jean-Francois Mosnier, Tamara Matysiak-Budnik
Summary: Pepsinogen testing by chemiluminescent enzyme immunoassay is accurate for the detection of corpus atrophic gastritis, while IL-6 and HE-4 may be beneficial for the detection of antrum atrophic gastritis.
Article
Biochemistry & Molecular Biology
Camille Evrard, Thomas Aparicio, Emilie Soularue, Karine Le Malicot, Jerome Desrame, Damien Botsen, Farid El Hajbi, Daniel Gonzalez, Come Lepage, Olivier Bouche, David Tougeron
Summary: This study aims to evaluate the efficacy and safety of FOLFIRI with Durvalumab +/- Tremelimumab combination therapy for gastric/GEJ adenocarcinoma. The treatment was associated with a high incidence of adverse events, most commonly neutropenia. Only one serious adverse event was related to chemotherapy, but it was not considered treatment-related according to the investigator's assessment.
Article
Oncology
Thierry Andre, David Tougeron, Guillaume Piessen, Christelle de la Fouchardiere, Christophe Louvet, Antoine Adenis, Marine Jary, Christophe Tournigand, Thomas Aparicio, Jerome Desrame, Astrid Lievre, Marie-Line Garcia-Larnicol, Thomas Pudlarz, Romain Cohen, Salome Memmi, Dewi Vernerey, Julie Henriques, Jeremie H. Lefevre, Magali Svrcek
Summary: The NEONIPIGA study found that perioperative platinum-based chemotherapy is the standard treatment for resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma. However, the efficacy of perioperative chemotherapy in gastric/GEJ adenocarcinoma with deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) remains debatable. This study showed that neoadjuvant nivolumab-based therapy is feasible, associated with no unexpected toxicity, and has a high pathological complete response (pCR) rate in patients with dMMR/MSI-H resectable gastric/GEJ adenocarcinoma.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Come Lepage, Jean-Marc Phelip, Astrid Lievre, Karine Le-Malicot, Laetitia Dahan, David Tougeron, Christos Toumpanakis, Frederic Di-Fiore, Catherine Lombard-Bohas, Ivan Borbath, Romain Coriat, Thierry Lecomte, Rosine Guimbaud, Caroline Petorin, Jean-Louis Legoux, Pierre Michel, Jean-Yves Scoazec, Denis Smith, Thomas Walter
Summary: This study aimed to evaluate the efficacy of lanreotide autogel 120 mg as maintenance treatment for aggressive duodeno-pancreatic neuroendocrine tumors. The results showed that the lanreotide group had a progression-free survival (PFS) of 73.1% at 6 months, compared to 54.2% in the placebo group. The median PFS was 19.4 months in the lanreotide group and 7.6 months in the placebo group.
EUROPEAN JOURNAL OF CANCER
(2022)
Review
Oncology
Julien Taieb, Magali Svrcek, Romain Cohen, Debora Basile, David Tougeron, Jean-Marc Phelip
Summary: Microsatellite unstable colorectal cancers are characterized by DNA mismatch repair deficiency and have prognostic and predictive implications. Immune checkpoint inhibitors have shown remarkable effectiveness in this type of cancer, but resistance remains a challenge.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Sebastian Stintzing, Kathrin Heinrich, David Tougeron, Dominik Paul Modest, Ingo Schwaner, Jan Eucker, Rudolf Pihusch, Martina Stauch, Florian Kaiser, Christoph Kahl, Meinolf Karthaus, Christian Mueller, Christof Burkart, Anke Reinacher-Schick, Stefan Kasper-Virchow, Ludwig Fischer von Weikersthal, Beate Krammer-Steiner, Gerald Wolfgang Prager, Julien Taieb, Volker Heinemann
Summary: This clinical trial investigated the efficacy of triplet chemotherapy combined with either cetuximab or bevacizumab in previously untreated BRAF(V600E)-mutant metastatic colorectal cancer (mCRC) patients. The results showed that bevacizumab-based chemotherapy remains the preferable first-line treatment for patients with BRAF(V600E)-mutant mCRC.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Gastroenterology & Hepatology
Mathias Brugel, Thibault Marulier, Camille Evrard, Claire Carlier, David Tougeron, Guillaume Piessen, Stephanie Truant, Anthony Turpin, Nicolas Williet, Damien Botsen, Mathilde Brasseur, Marine Perrier, Olivier Bouche
Summary: This study investigated the genetic counselling referral practices for pancreatic adenocarcinoma (PA) in France and assessed the implementation of international guidelines. The results showed inadequate referral for genetic counselling, with a significant portion of patients not receiving the recommended counselling despite indications. The study also identified factors influencing the referral, including suspected CDKN2A or BRCA mutations, familial pancreatic cancer history, and controlled disease with first-line platinum-based chemotherapy, while older age and locally advanced PA decreased the likelihood of referral.
Article
Medicine, General & Internal
Malgorzata Osmola, Caroline Hemont, Nicolas Chapelle, Marie-Anne Vibet, David Tougeron, Driffa Moussata, Dominique Lamarque, Edith Bigot-Corbel, Damien Masson, Justine Blin, Maxime Leroy, Regis Josien, Jean-Francois Mosnier, Jerome Martin, Tamara Matysiak-Budnik
Summary: Despite the global decrease in gastric cancer incidence, there has been an increase in recent years among young patients, particularly females. The cause of this new type of gastric cancer is still unknown, but autoimmunity may play a role. A study was conducted to analyze the prevalence of several autoantibodies in patients with chronic atrophic gastritis (CAG) compared to control patients. The results showed that ANA positivity was significantly higher in autoimmune gastritis patients (AIG) compared to non-autoimmune gastritis patients (NAIG) and control patients, while APCA and AIFA positivity were confirmed in AIG. Overall, the study did not support an overrepresentation of common autoantibodies in CAG patients.
Article
Oncology
Pauline Marolleau, David Tougeron, Benoit Allignet, Romain Cohen, David Sefrioui, Blandine Gallet, Frederic Dumont, Rosine Guimbaud, Emily Alouani, Guillaume Passot, Gregoire Desolneux, Francois Ghiringhelli, Frederic Marchal, Farouk Mourthadhoi, Romain Coriat, Romain Desgrippes, Christophe Locher, Gael Goujon, Gaetan Des Guetz, Thomas Aparicio, Etienne Paubelle, Aurelien Dupre, Christelle de la Fouchardiere
Summary: Our study aimed to describe metastasectomy results, characterize histological response, and evaluate pathological complete response (pCR) rate in patients with dMMR/MSI mCRC. We retrospectively reviewed data from all consecutive patients with dMMR/MSI mCRC who underwent surgical metastasectomy between January 2010 and June 2021 in 17 French centers. The primary outcome was to assess the pCR rate defined by tumor regression grade (TRG) 0.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
J. Y. Blay, C. Cropet, S. Mansard, Y. Loriot, C. De La Fouchardiere, J. Haroche, D. Topart, D. Tougeron, B. You, A. Italiano, V. Le Brun-Ly, J. M. Ferrero, N. Penel, M. Fabbro, X. Troussard, D. Malka, I. Ray-Coquard, S. Leboulleux, A. Flechon, E. Maubec, J. Charles, S. Dalle, S. Taieb, G. C. T. E. Garcia, A. M. Mandache, N. Colignon, M. Gavrel, F. Nowak, N. Hoog Labouret, C. Mahier Ait Oukhatar, C. Gomez-Roca
Summary: Vemurafenib demonstrates efficacy and prolonged PFS in advanced tumors with BRAF mutations other than melanoma and NSCLC. This therapy is effective for various tumor types including HCL, ECD, ovarian carcinoma, gliomas, ganglioglioma, and sarcomas.